Antineoplastic Combined Chemotherapy Protocols

5 trials

Sponsors

Manabu Muto, Center of Molecular Immunology (CIM), Center of Molecular Immunology

Conditions

CD20+ B-cell non-Hodgkin lymphoma of Low-Grade (Follicular or small lymphocytic lymphoma ) or aggressive (Diffuse large B-cell lymphoma (DLBCL) or Follicular stage III-IV.Castration resistant prostate cancerColon adenocarcinoma phase IV or evolvable metastatic diseaseEsophageal cancer, gastric cancer, small bowel cancer, colorectal cancerNon Small Cell Lung Cancer

Phase 2

1E10 anti-idiotype vaccine, metastatic colon, phase II.

Active, not recruitingRPCEC00000006

Center of Molecular Immunology (CIM)Colon adenocarcinoma phase IV or evolvable metastatic disease

Start: 2002-07-19Target: 40Updated: 2026-03-30

Phase 3

CIMAvax-EGF® in metastatic asymptomatic or mildly symptomatic Castration Resistant Prostate Cancer patients. Phase II-III Clinical Trial

Active, not recruitingRPCEC00000291

Center of Molecular Immunology (CIM)Castration resistant prostate cancer

Start: 2018-10-01Updated: 2026-03-30

Phase 4

CIMAbior® in CD20-positive B-cell Non-Hodgkin Lymphoma

Active, not recruitingRPCEC00000251

Center of Molecular ImmunologyCD20+ B-cell non-Hodgkin lymphoma of Low-Grade (Follicular or small lymphocytic lymphoma ) or aggressive (Diffuse large B-cell lymphoma (DLBCL) or Follicular stage III-IV.

Start: 2017-10-01Updated: 2026-03-30

Unknown Phase

Combined NGcGM3/VSSP and Nimotuzumab in advanced non-small cell lung cancer (NSCLC)

Active, not recruitingRPCEC00000270

Center of Molecular Immunology (CIM)Non Small Cell Lung Cancer

Start: 2018-04-30Target: 30Updated: 2026-03-30

The feasibility study of FOLFOX therapy in gastrointestinal cancer patients undergoing hemodialysis

Active, not recruitingJPRN-jRCTs051190120

Manabu MutoEsophageal cancer, gastric cancer, small bowel cancer, colorectal cancer

Start: 2020-03-23Target: 15Updated: 2025-07-18